A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control

Current Medical Research and Opinion

Volumn 22, Issue SUPPL. 2, 2006, Pages

  Seufert, Jochen ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Glycemic control; Metformin; Pioglitazone; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; COMPETACT; ENDOTHELIN 1; GELATINASE B; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS PIOGLITAZONE; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AREA UNDER THE CURVE; BIOEQUIVALENCE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PLEIOTROPY; REVIEW; SIDE EFFECT; TABLET; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; THIAZOLIDINEDIONES;

EID: 33748935337     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X121002     Document Type: Review

References (96)

1. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-58
2. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675-91
3. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 2004;33:283-303
4. Basu R, Basu A, Johnson CM, et al. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 2004;53:2042-50
5. Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000;21:585-618
6. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-78
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
8. International Diabetes Federation Clinical Guidelines Taskforce. Global guideline for type 2 diabetes. Brussels; International Diabetes Federation, 2005
9. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29:S4-42
10. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). The UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
11. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
12. Ovalle F, Bell DSH. Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. Diabetes Obes Metab 2004;6:363-6
13. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90
14. Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998;98:398-404
15. Pyorala M, Miettinen H, Halonen P, et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20:538-44
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
17. Colhoun HM, Betteridge DJ, Durrington PN, et al.; on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
19. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
20. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-9
21. Charbonnel BH, Matthews DR, Schernthaner G, et al.; on behalf of the QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005a;22:399-405
22. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409
23. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metabol Res Rev 2005;21:167-74
24. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptory (PPARγ). J Biol Chem 1995;270:12953-6
25. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49
26. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-94
27. Kawamori R, Matsuhisa M, Kinoshita J, et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 1998;41:35-43
28. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517-23
29. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-41
30. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13:696-704
31. Diani AR, Sawada G, Wyse B, et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004;286:E116-22
32. Zeender E, Maedler K, Bosco D, et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004;89:5059-66
33. Tan MH, Glazer NB, Johns D, et al. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004;20:723-8
34. Urquhart R, Tan MH, Mariz S, et al. Long-term (2-year) effects on HOMA-%S, an estimate of insulin sensitivity, of pioglitazone, gliclazide and metformin as add-on therapies in patients with T2DM. Diabetes 2004;53(Suppl 2):A150 [abstract]
35. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004;21:568-76
36. Hamdy O, Soodini G, Martens J, et al. Pioglitazone preserves pancreatic β-cells in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 2005:54(Suppl 1):A146 [592-P] [abstract]
37. Buchanan TA, Xiang AH, Kjos SL, et al. Diabetes rates and β-cell function in the pioglitazone prevention of diabetes (PIPOD) study. Diabetes 2005;54(Suppl 1):A39 [abstract]
38. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs 2005;65:1-13
39. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51(Suppl 1):S134-7
40. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabets 2000;108:S234-42
41. Takeda Pharmaceuticals America Inc. Actos (pioglitazone hydrochloride) tablets prescribing information (online). Available from http://www.actos.com [Last accessed 12 May 2006]
42. Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996;36:1012-21
43. Karim A, Cao C, Perez A. Bioequivalency of pioglitazone and metformin combination tablets vs coadministration tablet. J Clin Pharmacol 2005;45:1090 [A97] [abstract]
44. Karim A, Cao C, Perez A. Food effects of pharmacokinetics of pioglitazone and metformin administered as a combination tablet. J Clin Pharmacol 2005;45:1090 [A98] [abstract]
45. Charbonnel B, Scheen A. Combination therapy with pioglitazone and either metformin or sulfonylurea: glycemic results from PROactive. Diabetes 2006;55:A478 [abstract]
46. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998;21:87-92
47. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11
48. Herz M, Johns D, Reviriego J, et al.; for the GLAB study group. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95
49. Rosenblatt S, Miskin B, Glazer NB, et al. and the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
50. Scherbaum WA, Goke B; German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589-95
51. Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events). Lancet 2005;366:1279-89
52. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocrin Pract 2001;7:162-9
53. Göke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002;1:329-36
54. Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
55. Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11
56. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637-45
57. Schernthaner G, Matthews D, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76
58. Tan M, Baksi A, Kubalski P, et al.; for the GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28:544-50
59. Betteridge DJ, Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48:2477-81
60. Deeg MA, Goldberg RB, Buse JB, et al. The comparative effects of pioglitazone and rosiglitazone on lipoprotein sub-fractions in patients with type 2 diabetes and dyslipidemia. Diabetes 2005;54(Suppl 1):A234-5 [960-P] [abstract]
61. Derosa G, Cicero AFG, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54
62. Derosa G, Cicero AFG, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5-13
63. Derosa G, Cicero AFG, Ragonesi PD, et al. Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Diabetes 2006;55:A496 [abstract]
64. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized, controlled trial. JAMA 2000;283:1695-702
65. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
66. van Wijk JP, de Koning EJ, Martens EP, et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9
67. Comaschi MA, Di Pietro C, Fionda A, et al. Efficacy and safety of pioglitazone in addition to SU or met vs. FC with met plus glyburide in T2 diabetes pts. Diabetes 2006;55:A473 [abstract]
68. Torre E, Ponzani P, Menozzi F, et al. The efficacy and safety of pioglitazone in addition to SU or metformin vs fixed combination of metformin plus glibenclamide on diabetic dyslipidemia. Diabetologia 2006; in press [abstract]
69. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15:755-72
70. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6
71. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. Results from the Pioneer study. J Am Coll Cardiol 2005;45:1925-3
72. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes. Influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17:211-7
73. Shin JJ, Rothman J, Farag A, et al. Role of oral anti-diabetic agents in modifying cardiovascular risk factors. Minerva Med 2003;94:401-8
74. Chu NV, Kong APS, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002;25:542-9
75. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005;54:2305-13
76. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9
77. Abbasi F, Chu JW, McLaughlin T, et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004;53:159-64
78. Dandona P, Aljada A, Chaudhuri A, et al. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord 2004;5:189-97
79. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005;257:100-9
80. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991;229:181-7
81. Grant PJ, Stickland MH, Booth NA, et al. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabetic Med 1991;8:361-5
82. Pampanelli S, Rinaldi T, Perriello G, et al. Effects of pioglitazone on coagulation and thrombosis in comparison to gliclazide in patients with type 2 diabetes. Diabetes 2004;53(Suppl 2):A140
83. Martin-Nizard F, Furman C, Delerive P, et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 2002;40:822-31
84. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation 2005;111:2525-31
85. Matsumoto K, Sera Y, Abe Y, et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004;64:225-8
86. Choi D, Kim S-K, Choi S-H, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004;27:2654-60
87. Marx N, Wöhrle J, Nusser T, et al. Pioglitazone reduces neointima formation after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 2005;112:2792-8
88. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:E5
89. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
90. Erdmann E. The Effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and pre-existing myocardial infarction - data from the PROactive study [abstract]. Presented at the American Heart Association, Dallas, 13-16 Nov, 2005. Available from http://www.proactive- results. com [Last accessed 12 May 2006]
91. Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006;66:85-109
92. Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005;70:53-62
93. Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabetic Med 2005;22:986-93
94. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41
95. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Med 2005;22:973-9
96. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-75